FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4297256306> ?p ?o ?g. }

• W4297256306 endingPage "835" @default.
• W4297256306 startingPage "825" @default.
• W4297256306 abstract "To evaluate the value of time-serial CT radiomics features in predicting progression-free survival (PFS) for lung adenocarcinoma (LUAD) patients after epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) therapy.LUAD patients treated with EGFR-TKIs were retrospectively included from three independent institutes and divided into training and validation cohorts. Intratumoral and peritumoral features were extracted from time-serial non-contrast chest CT (including pre-therapy and first follow-up images); moreover, the percentage variation per unit time (day) was introduced to adjust for the different follow-up periods of each patient. Test-retest was performed to exclude irreproducible features, while the Boruta algorithm was used to select critical radiomics features. Radiomics signatures were constructed with random forest survival models in the training cohort and compared against baseline clinical characteristics through Cox regression and nonparametric testing of concordance indices (C-indices).The training cohort included 131 patients (74 women, 56.5%) from one institute and the validation cohort encompassed 41 patients (24 women, 58.5%) from two other institutes. The optimal signature contained 10 features and 7 were unit time feature variations. The comprehensive radiomics model outperformed the pre-therapy clinical characteristics in predicting PFS (training: 0.78, 95% CI: [0.72, 0.84] versus 0.55, 95% CI: [0.49, 0.62], p < 0.001; validation: 0.72, 95% CI: [0.60, 0.84] versus 0.54, 95% CI: [0.42, 0.66], p < 0.001).Radiomics signature derived from time-serial CT images demonstrated optimal prognostic performance of disease progression. This dynamic imaging biomarker holds the promise of monitoring treatment response and achieving personalized management.• The intrinsic tumor heterogeneity can be highly dynamic under the therapeutic effect of EGFR-TKI treatment, and the inevitable development of drug resistance may disrupt the duration of clinical benefit. Decision-making remained challenging in practice to detect the emergence of acquired resistance during the early response phase. • Time-serial CT-based radiomics signature integrating intra- and peritumoral features offered the potential to predict progression-free survival for LUAD patients treated with EGFR-TKIs. • The dynamic imaging signature allowed for prognostic risk stratification." @default.
• W4297256306 created "2022-09-28" @default.
• W4297256306 creator A5014860513 @default.
• W4297256306 creator A5015864051 @default.
• W4297256306 creator A5017070668 @default.
• W4297256306 creator A5020079804 @default.
• W4297256306 creator A5028221389 @default.
• W4297256306 creator A5033411069 @default.
• W4297256306 creator A5051363890 @default.
• W4297256306 creator A5061332222 @default.
• W4297256306 creator A5065254832 @default.
• W4297256306 creator A5087795569 @default.
• W4297256306 creator A5091240231 @default.
• W4297256306 date "2022-09-27" @default.
• W4297256306 modified "2023-10-18" @default.
• W4297256306 title "Prognostic analysis and risk stratification of lung adenocarcinoma undergoing EGFR-TKI therapy with time-serial CT-based radiomics signature" @default.
• W4297256306 cites W1607191560 @default.
• W4297256306 cites W1731559625 @default.
• W4297256306 cites W1987054640 @default.
• W4297256306 cites W2012124753 @default.
• W4297256306 cites W2017837130 @default.
• W4297256306 cites W2019607817 @default.
• W4297256306 cites W2022670843 @default.
• W4297256306 cites W2033278321 @default.
• W4297256306 cites W2040299716 @default.
• W4297256306 cites W2060672294 @default.
• W4297256306 cites W2062265555 @default.
• W4297256306 cites W2063771321 @default.
• W4297256306 cites W2080860848 @default.
• W4297256306 cites W2081437435 @default.
• W4297256306 cites W2096198395 @default.
• W4297256306 cites W2102708672 @default.
• W4297256306 cites W2108371618 @default.
• W4297256306 cites W2111662961 @default.
• W4297256306 cites W2128739912 @default.
• W4297256306 cites W2129360604 @default.
• W4297256306 cites W2132157071 @default.
• W4297256306 cites W2154149901 @default.
• W4297256306 cites W2166084034 @default.
• W4297256306 cites W2174661749 @default.
• W4297256306 cites W2225538867 @default.
• W4297256306 cites W2303551941 @default.
• W4297256306 cites W2327203407 @default.
• W4297256306 cites W2338137334 @default.
• W4297256306 cites W2461805626 @default.
• W4297256306 cites W2470491115 @default.
• W4297256306 cites W2523312410 @default.
• W4297256306 cites W2530038065 @default.
• W4297256306 cites W2599895745 @default.
• W4297256306 cites W2620325446 @default.
• W4297256306 cites W2763355946 @default.
• W4297256306 cites W2766675183 @default.
• W4297256306 cites W2775847164 @default.
• W4297256306 cites W2789301976 @default.
• W4297256306 cites W2801894005 @default.
• W4297256306 cites W2848312316 @default.
• W4297256306 cites W2899315113 @default.
• W4297256306 cites W2900734487 @default.
• W4297256306 cites W2903686982 @default.
• W4297256306 cites W2903724987 @default.
• W4297256306 cites W2904258904 @default.
• W4297256306 cites W2914516088 @default.
• W4297256306 cites W2950230071 @default.
• W4297256306 cites W2983529249 @default.
• W4297256306 cites W3006178210 @default.
• W4297256306 cites W3011780798 @default.
• W4297256306 cites W3014792565 @default.
• W4297256306 cites W3088851959 @default.
• W4297256306 doi "https://doi.org/10.1007/s00330-022-09123-5" @default.
• W4297256306 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36166088" @default.
• W4297256306 hasPublicationYear "2022" @default.
• W4297256306 type Work @default.
• W4297256306 citedByCount "6" @default.
• W4297256306 countsByYear W42972563062023 @default.
• W4297256306 crossrefType "journal-article" @default.
• W4297256306 hasAuthorship W4297256306A5014860513 @default.
• W4297256306 hasAuthorship W4297256306A5015864051 @default.
• W4297256306 hasAuthorship W4297256306A5017070668 @default.
• W4297256306 hasAuthorship W4297256306A5020079804 @default.
• W4297256306 hasAuthorship W4297256306A5028221389 @default.
• W4297256306 hasAuthorship W4297256306A5033411069 @default.
• W4297256306 hasAuthorship W4297256306A5051363890 @default.
• W4297256306 hasAuthorship W4297256306A5061332222 @default.
• W4297256306 hasAuthorship W4297256306A5065254832 @default.
• W4297256306 hasAuthorship W4297256306A5087795569 @default.
• W4297256306 hasAuthorship W4297256306A5091240231 @default.
• W4297256306 hasBestOaLocation W42972563061 @default.
• W4297256306 hasConcept C118552586 @default.
• W4297256306 hasConcept C126322002 @default.
• W4297256306 hasConcept C126838900 @default.
• W4297256306 hasConcept C143998085 @default.
• W4297256306 hasConcept C160798450 @default.
• W4297256306 hasConcept C16568411 @default.
• W4297256306 hasConcept C2778559731 @default.
• W4297256306 hasConcept C2779889316 @default.
• W4297256306 hasConcept C50382708 @default.
• W4297256306 hasConcept C71924100 @default.
• W4297256306 hasConcept C72563966 @default.

• next